Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager Portfolio & Delivery advances PMO maturity while ensuring disciplined execution of business system implementations and sustainment initiatives across the organization. This role is responsible for strengthening portfolio governance, modernizing visibility through advanced dashboarding and AI-enabled risk and capacity forecasting, and establishing structured intake and prioritization processes that enable predictable, scalable delivery. In addition, this position directly manages high-impact or strategically significant projects to ensure successful execution and model delivery excellence within the PMO framework. As the organization evolves beyond initial commercial launch, this position ensures IS operates with data-driven transparency, governance rigor, and execution discipline.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Number of Employees
251-500 employees